- Active Pharmaceutical Ingredients
- Varenicline tartrate
- Aprepitant, Fosapitant Intermediates
- Fosaprepitant Dimeglumine
- Vildagliptin
- Efinaconazole
- Luliconazole Intermediate
- Gadoterate Meglumine
- Succinyl Alcohol Intermediate
- Mirabillon Intermediate
- Atazanavir Intermediate
- Intermediate
- Varenicline tartrate
- Aprepitant 287930-73-8
- Aprepitant 127852-28-2
- Aprepitant 287930-75-0
- Aprepitant 200000-59-5
- Aprepitant 155742-64-6
- Aprepitant 252742-72-6
- Fosaprepitant Dimeglumine 990-91-0
- Fosaprepitant Dimeglumine 265121-01-5
- Vildagliptin 207557-35-5
- Vildagliptin 702-82-9
- Efinaconazole 144230-50-2
- Efinaconazole 133775-25-4
- Efinaconazole 127000-90-2
- Gadoterate Meglumine
- Mirabegron
- Luliconazole 98873-55-3
- Luliconazole 126534-31-4
- Atazanavir sulfate
- Bortezomib 179324-87-9
- Bortezomib 114457-94-2
- Bortezomib 205393-22-2
- Brinzolamide
- Rivaroxaban Intermediate 446292-08-6
- Rivaroxaban Intermediate 446292-07-5
- Cinacalcet Hydrochloride 1005450-55-4
- Cinacalcet Hydrochloride 585-50-2
- Eletriptan Intermediate
- Indacaterol intermediate 312753-53-0
- Indacaterol intermediate 173140-90-4
- Sitagliptin Intermediate
- Fosanavir Calcium Intermediate
Popular information
Antitumor drugs Bortezomib 179324-69-7
【Catalog number】AP0100
【CAS #】 179324-69-7
【Molecular formula】 C19H25BN4O4
【Product Brief】US-DMF No. 22884 Bortezomib, the English name is Bortezomib, and the American Chemical Abstracts Registration Number is cas179324-69-7.
Antitumor drugs
Bortezomib
CAS 179324-69-7
US-DMF No. 22884
Alias [(1R) -3-methyl-1-[[((2S) -1-oxo-3-phenyl-2-[(pyrazinyl) amino] propyl] amino] butyl] -boronic acid; Patzomi
Catalog number AP0100
CAS # 179324-69-7
Molecular formula C19H25BN4O4
Molecular weight 384.24
Structural formula
Product introduction
CAS 179324-69-7
US-DMF No. 22884 Bortezomib, the English name is Bortezomib, and the American Chemical Abstracts Registration Number is cas179324-69-7.
Bortezomib (cas 179324-69-7) is a reversible inhibitor of 26S proteasome chymotrypsin-like activity in mammalian cells. In vitro tests have proven that bortezomib is cytotoxic to many types of cancer cells. Preclinical tumor model in vivo tests have demonstrated that bortezomib can delay tumor growth, including multiple myeloma. This product is used for the treatment of patients with multiple myeloma, and its effectiveness is based on its effectiveness.
VIWIT 沪ICP备12014533号-1
